GABRIEL SCHWARTZ: Open Payments
NPI 1598148173 · SAN FRANCISCO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$21,010 in 33 payments from 3 companies in 2025. Trend: 2023 $34,847 · 2024 $57,896 · 2025 $21,010
Speaker / faculty: $15,540Travel & lodging: $2,920Consulting: $1,640Food & beverage: $910
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $8,090 |
| AstraZeneca Pharmaceuticals LP | 15 | $7,266 |
| Incyte Corporation | 8 | $5,654 |
Products named: FRUZAQLA, Pemazyre.
Industry payments across CA — which companies pay providers there.
